Verrica Pharmaceuticals Inc.

NasdaqGM:VRCA Stock Report

Market Cap: US$56.3m

Verrica Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:VRCA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
27 Aug 24SellUS$77,473P. Terence KohlerIndividual29,719US$2.66
27 Aug 24SellUS$35,161Gary GoldenbergIndividual13,489US$2.66
27 Aug 24SellUS$87,849Joe BonaccorsoIndividual33,702US$2.66
27 Aug 24SellUS$93,091Christopher HayesIndividual35,713US$2.66
27 Aug 24SellUS$88,636Ted WhiteIndividual34,000US$2.66
23 Jul 24SellUS$153,477Christopher HayesIndividual21,740US$7.06
23 Jul 24SellUS$180,557Joe BonaccorsoIndividual25,576US$7.06
23 Jul 24SellUS$130,653Gary GoldenbergIndividual18,507US$7.06
23 Jul 24SellUS$230,306Ted WhiteIndividual32,623US$7.06

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VRCA?
Owner TypeNumber of SharesOwnership Percentage
Institutions13,851,53115.3%
Hedge Funds16,564,50418.3%
General Public19,199,56721.2%
Individual Insiders40,949,23845.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 113.5%.

Top Shareholders

Top 25 shareholders own 77.35% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
41.7%
Paul Manning
37,804,145US$23.5m179%no data
10.1%
Armistice Capital LLC
9,134,817US$5.7m0%0.14%
8.2%
Caligan Partners, LP
7,429,687US$4.6m0%1.04%
3.59%
Perceptive Advisors LLC
3,249,669US$2.0m-54.2%0.06%
2.86%
Boothbay Fund Management, LLC
2,587,046US$1.6m0%0.05%
2.08%
The Vanguard Group, Inc.
1,879,914US$1.2m46.1%no data
2.07%
Sean Stalfort
1,873,800US$1.2m305%no data
1.31%
BlackRock, Inc.
1,189,559US$739.2k9.59%no data
0.98%
Jayson Rieger
889,881US$553.0k244%no data
0.58%
State Street Global Advisors, Inc.
523,118US$325.1k2.01%no data
0.53%
Geode Capital Management, LLC
477,269US$296.6k4.78%no data
0.45%
Sovran Advisors, LLC
407,050US$252.9k0%0.04%
0.4%
Morgan Stanley, Investment Banking and Brokerage Investments
361,427US$224.6k126%no data
0.39%
Heights Capital Management, Inc.
351,142US$218.2k0%0.06%
0.29%
Rhumbline Advisers Ltd Partnership
266,093US$165.3k975%no data
0.28%
PBM Capital Group LLC
256,634US$159.5k0%1.64%
0.26%
Renaissance Technologies LLC
233,300US$145.0k57.7%no data
0.24%
Northern Trust Global Investments
217,032US$134.9k-0.95%no data
0.19%
BML Capital Management, LLC
174,651US$108.5k-2.97%0.07%
0.19%
UBS Asset Management AG
174,062US$108.2k1,710%no data
0.16%
Bank of America Corporation, Asset Management Arm
143,618US$89.2k350%no data
0.14%
Two Sigma Investments, LP
128,444US$79.8k11.4%no data
0.12%
David Zawitz
110,000US$68.4k0%no data
0.11%
Ted White
103,467US$64.3k0%no data
0.099%
Mariner, LLC
89,778US$55.8k-0.18%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/05 01:40
End of Day Share Price 2025/03/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Verrica Pharmaceuticals Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Brian Kemp DolliverBrookline Capital Markets
Oren LivnatH.C. Wainwright & Co.